Niraparib Tosylate

甲苯磺酸尼拉帕利

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameNiraparib Tosylate
Drug Alias NameNiraparibum甲苯磺酸尼拉帕尼尼拉帕利Niraparib Tosylate MonohydrateZL-2306对甲苯磺酸盐一水合物 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerLow-grade Glioma +[48] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Approved Indications in ChinaOvarian Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2017/03/27
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTesaro IncMerck Sharp & Dohme Corp
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDana-Farber Cancer InstituteQuotient Sciences Llc(Formerly Qs Pharma)Glaxosmithkline Plc +[24] 
Inactive CompaniesTempus AIThe University Of California DavisThe Netherlands Cancer Institute +[11] 
Active IndicationsUveal melanomaMetastatic breast cancerLow-grade Glioma +[27] 
Inactive IndicationsGastroesophageal Junction NeoplasmsSolid tumoursHepatic Insufficiency +[21] 

Other Information

ATC CodeL01XK02
Related LinksWikipediaDrugBankKEGG